West Nyack, NY, United States of America

Minu D Dutia


Average Co-Inventor Count = 4.5

ph-index = 8

Forward Citations = 167(Granted Patents)


Company Filing History:


Years Active: 1991-2006

Loading Chart...
17 patents (USPTO):Explore Patents

Title: Unveiling the Innovations of Inventor Minu D Dutia

Introduction: Inventor Minu D Dutia, based in West Nyack, NY, is a prominent figure in the field of innovation with an impressive portfolio of 17 patents under his name. His dedication to scientific advancement has led to groundbreaking discoveries in the realm of protein kinase inhibitors, particularly in the development of tricyclic compounds.

Latest Patents: Among his notable inventions are the tricyclic protein kinase inhibitors, compounds of formula 1 that exhibit potent inhibitory effects on protein tyrosine kinase. These compounds have shown promising potential as antiproliferative agents, offering new avenues for therapeutic interventions in various medical conditions.

Career Highlights: Minu D Dutia has made significant contributions to the field of pharmaceuticals through his work at renowned companies such as American Cyanamid Company and Wyeth. His expertise and innovative approach have been instrumental in the development of novel drugs and treatment modalities that have the potential to impact the lives of many.

Collaborations: Throughout his career, Minu D Dutia has collaborated with talented individuals in the field, including notable coworkers such as Jonathan D Bloom and Thomas H Claus. These collaborations have facilitated the exchange of ideas, knowledge, and expertise, resulting in the successful realization of innovative projects and patents.

Conclusion: In conclusion, Minu D Dutia stands as a visionary inventor whose pioneering work in the development of protein kinase inhibitors has significantly contributed to the advancement of medical science. His unwavering dedication to innovation and collaboration underscores his position as a trailblazer in the industry, leaving a lasting impact on the landscape of pharmaceutical research and development.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…